Overview

* Rezolute ( RZLT ) fiscal Q1 net loss widens to $18.2 mln from $15.4 mln a year ago

* Operating expenses for fiscal Q1 rise to $19.8 mln from $16.9 mln last year

Result Drivers

* R&D EXPENSES - Increase in R&D expenses due to higher clinical trial activities and employee-related costs

* G&A EXPENSES - Rise in G&A expenses attributed to professional fees and increased headcount

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Net -$18.15

Income mln

Q1 -$19.82

Income mln

From

Operatio

ns

Q1 $19.82

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for Rezolute Inc ( RZLT ) is $14.00, about 33.2% above its November 5 closing price of $9.35

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)